Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Citicoline. Ferrer Internacional.

A V Alexandrov1

  • 1Department of Neurology, University of Texas, Houston 77030, USA. avalexandrov@worldnet.att.net

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis.

European journal of neurology·2020
Same author

Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity.

European journal of neurology·2020
Same author

[Biomechanical Analysis of Posture and Movement Coordination in Standing Human During Trunk Bending in the Sagittal Plane].

Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova·2019
Same author

Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis.

European journal of neurology·2018
Same author

Differential leukocyte counts on admission predict outcomes in patients with acute ischaemic stroke treated with intravenous thrombolysis.

European journal of neurology·2018
Same author

Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study.

European journal of neurology·2017
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Citicoline, initially for stroke treatment, is being explored for Alzheimer's disease (AD). Patents support its use in reducing brain tissue damage from ischemic stroke.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Citicoline was developed by Ferrer for stroke treatment.
  • Interneuron obtained US and Canadian rights in 1993.
  • It is also being investigated for Alzheimer's disease (AD).

Purpose of the Study:

  • To investigate the development and patent landscape of citicoline.
  • To understand its potential therapeutic applications in neurological disorders.

Main Methods:

  • Review of development history and licensing agreements.
  • Analysis of patent filings related to citicoline's neurological applications.

Main Results:

  • Citicoline development for stroke in the US involved Interneuron and Takeda.
  • A patent was issued for citicoline's role in protecting brain tissue post-ischemic stroke.

Related Experiment Videos

  • Takeda decided not to pursue development, leading Interneuron to seek new partnerships.

    • Conclusions:

    • Citicoline has established applications in stroke treatment and emerging potential in Alzheimer's disease.
    • Intellectual property has been secured for its neuroprotective effects in stroke.